dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Kaczmarczyk, Bartosz |
dc.contributor.author | Álvarez, Rebeca |
dc.contributor.author | Navas-López, Víctor Manuel |
dc.contributor.author | Gallego-Fernández, Carmen |
dc.contributor.author | Moreno-Álvarez, Ana |
dc.contributor.author | Clemente Bautista, Susana |
dc.contributor.author | Salvador-Martín, Sara |
dc.date.accessioned | 2021-05-17T12:17:43Z |
dc.date.available | 2021-05-17T12:17:43Z |
dc.date.issued | 2021-01-08 |
dc.identifier.citation | Salvador-Martín S, Kaczmarczyk B, Álvarez R, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, et al. Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Pharmaceutics. 2021 Jan 8;13(1):77. |
dc.identifier.issn | 1999-4923 |
dc.identifier.uri | https://hdl.handle.net/11351/5958 |
dc.description | Biomarcador; Expressió gènica; Malaltia inflamatòria intestinal |
dc.description.sponsorship | This research was funded by Instituto de Salud Carlos III (grants numbers PI16/00559 and PI19/00792), Consejería de Educación y Deporte de la Comunidad de Madrid (grant number PEJ16/MED/AI-1260), and by the Gregorio Marañón Health Research Institute (grant number PRE-2018-2). The study was cofunded by European Regional Develompment Funds (FEDER) from the European Commission, “A way of making Europe”. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Pharmaceutics;13(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Intestins - Inflamació |
dc.subject | Medicaments - Administració |
dc.subject | Adolescents |
dc.subject.mesh | Inflammatory Bowel Diseases |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Adolescent |
dc.title | Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/pharmaceutics13010077 |
dc.subject.decs | enfermedad inflamatoria intestinal |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | adolescente |
dc.relation.publishversion | https://doi.org/10.3390/pharmaceutics13010077 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Salvador-Martín S, Kaczmarczyk B] Pharmacy Department, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain. [Álvarez R] Genomics Unit, Spanish Nacional Center for Cardiovascular Diseases (CNIC), 28029 Madrid, Spain. [Navas-López VM] Pediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Málaga, IBIMA Multidisciplinary Group for Pediatric Research, 29010 Málaga, Spain. [Gallego-Fernández C] Pharmacy Department, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain. [Moreno-Álvarez A] Pediatric Gastroenterology Unit, Department of Pediatrics, A Coruña University Hospital, 15006 A Coruña, Spain. [Clemente S] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33429950 |
dc.identifier.wos | 000610704100001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00559 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00792 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PEJ16%2FMED%2FAI-1260 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |